Acute erythroid leukemia (AEL) is a rare type of acute myeloid leukemia (AML) for which diagnostic criteria have been refined in the 2008 World Health Organization (WHO) classification of AML. The relationship of AEL to myelodysplastic syndromes (MDS) and to AML with myelodysplasia-related changes (AML-MRC) is not clearly defined. We conducted a retrospective, multi-institutional study of patients with AEL and compared them to patients with MDS or AML-MRC with erythroid hyperplasia (≥50% erythroid cells). Among a total of 124 patients with AEL, 32% had a history of MDS or chronic cytopenia, 32% had therapy-related disease, and 35% had de novo disease. 64% of patients had unfavorable AML risk-group karyotypes. FLT3 and RAS mutations were infrequent, occurring in 6% and 2%, respectively.
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Due to the relative rarity of AEL, few large studies have examined its clinical and genetic features. Although AEL is now separated from AML-MRC, many publications have emphasized certain similarities between these disease categories, such as the high frequency of a preceding diagnosis of MDS or presence of multilineage dysplasia, as well as similarities in the observed cytogenetic alterations. 5 AEL also has been shown to share similar karyotypic abnormalities with cases of AML with 20-30% blasts, previously categorized as refractory anemia with excess blasts in transformation (RAEB-t) in the FAB Classification of MDS. 6 Indeed, some leukemia experts have voiced concern that the lowered blast count of 20% of non-erythroid elements would lead to cases of MDS with excess blasts and transient erythroid hyperplasia being misdiagnosed as AEL. 7 AEL appears to have a relatively poor prognosis, with a median survival of 4-6 months. Cytogenetics appears to be a major factor in determining survival. 8 Although allogeneic stem cell transplantation improves the outcome of AEL patients, most of these studies were based on AEL as defined by the FAB (≥30% blasts) system. 9 No studies to date have reassessed AEL as currently defined in the 2008 WHO classification.
We studied the clinicopathologic and genetic features of 124 patients with AEL as defined using the criteria in the current WHO classification and examined their outcome in comparison to patients with MDS or AML-MRC associated with erythroid hyperplasia.
METHODS
For personal use only. However, many of these cases fulfilled WHO 2008 classification criteria for AML-MRC (dysplasia in at least 50% of cells in at least two lineages, MDS-related cytogenetics, and/or a history of MDS) and were used as a comparison group (see below). The patients' records were reviewed for any history of antecedent chemotherapy, radiation therapy, hematologic neoplasm, or cytopenia(s). Based on the clinical presentation, the patients were assigned to three groups:
AEL following MDS (MDS-AEL), comprising patients with a documented history of cytopenia(s) for at least 6 months preceding the diagnosis of AEL or a preceding diagnosis of MDS or MDS/MPN; therapy-related AEL (T-AEL), comprising patients who had an antecedent history of radiotherapy or chemotherapy or both; and de novo AEL (N-AEL), representing the patients who presented as acute onset disease with no history of MDS, chronic cytopenias, or therapy for an earlier neoplasm. Clinical follow-up information, including treatment modalities and overall survival (OS) from the date of AEL, was retrieved from the electronic medical records. All therapy with toxicity equivalent to standard "7+3" chemotherapy was classified as Research Council (UKMRC) criteria for AML. 15 The specific cytogenetic abnormalities that constitute these two cytogenetic risk groups are shown in Table 1 .
FLT3 and K-and N-RAS mutation analysis
A fluorescent-based multiplex PCR assay was used to detect internal tandem duplication (ITD) and D835 point mutations of the FLT3 gene using DNA isolated from bone marrow aspirate or peripheral blood samples, as previously described. 16 . K-RAS and N-RAS mutations were tested using PCR followed by pyrosequencing as described previously.
17

Statistical analysis
Fisher's exact test and Chi-square test were applied to categorical variables. Mann-Whitney test The correlation coefficient of the re-reviews was high (0.87, p<0.001 and 0.83, p<0.001 respectively for erythroid and blast percentages). The mean difference in erythroid cell percentage between the original review and re-review was 1.9% (p=0.04; paired t-test). The mean difference in the blast count between observers at initial review and re-review was 0.2% (p=0.68; paired t-test).
The clinical features of the AEL cases are summarized in Table 2 Table 3 .
Morphologic Findings
The morphologic features of the AEL cases are summarized in Table 2 . Most bone marrow core biopsy specimens were hypercellular and, by definition, bone marrow aspirate smears showed numerous erythroid elements comprising at least 50% of all cells on the smear. Morphologic dysplasia was commonly observed and was present in the erythroid lineage in almost all cases, and in megakaryocytes in most cases. The median blast count was 12% (range, 4-19%) of all nucleated cells and 32% (range, 20-58%) of all non-erythroid cells in the bone marrow.
Results of Conventional Cytogenetics and Mutation Analysis
The results of conventional cytogenetic analysis were available for 119 (96%) patients. Table 2 shows AEL cases in each cytogenetic risk group assignment using the IPSS and UKMRC schemes, as well as a summary of the most frequent cytogenetic abnormalities. Deletions and monosomies of chromosomes 5 and 7 were common and 43% of patients fulfilled criteria for a monosomal karyotype as defined by Breems et al. 18 Aside from the abnormalities shown in 
Treatment and Survival
Seventy-three of 124 (59%) patients received induction chemotherapy, followed by allogeneic bone marrow transplant (BMT) in 21 (17%) patients. Thirty-three (27%) patients did not receive induction chemotherapy; of these, two were treated with azacitidine, 2 with thalidomide, 2 with lenalidomide, and 1 with decitabine, and the remaining patients received supportive care only. 
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The OS of patients according to the UKMRC AML and the IPSS MDS Cytogenetic risk groups are shown in Figures 3A and 3B . The median OS of patients with and without deletion/loss of chromosome 5 was 5.5 and 23 months, respectively (p<0.0001, log rank test). The median OS of patients with and without deletion/loss of chromosome 7 was 7 months and 22 months, respectively (p=0.0002). Deletion/loss of chromosomes 5 and 7 occurred together in most cases.
There was no significant difference in OS between patients with and without +8, nor was there difference in OS between patients with a normal karyotype compared to an abnormal karyotype in the AML intermediate cytogenetic risk group. The median OS of patients with or without a monosomal karyotype was 6.5 and 10 months, respectively, p=0.02). However, UKMRC AML and IPSS cytogenetic risk groups were stronger predictors of OS than a monosomal karyotype. (Table   4 ). However, similar to AEL, there was a significant difference in OS between the intermediate and unfavorable UKMRC AML Cytogenetic risk groups among both the 35 AML-MRC cases with available cytogenetics (p=0.0004, log rank test) and the 39 MDS with erythroid hyperplasia cases with available cytogenetics (p=0.016, log rank test). In contrast, survival analysis of 179 MDS cases lacking erythroid hyperplasia (<50% erythroid elements) from UMASS showed a significant difference in OS based on blast count stratification (Table 4) .
Multivariate analysis by Cox proportional regression was performed analyzing OS and the following factors: age, gender, clinical subgrouping, treatment type, bone marrow cellularity, bone marrow erythroid percentage, bone marrow blast count, hemoglobin level, white blood count, absolute neutrophil count, platelet level, and AML cytogenetic risk group. Only the AML cytogenetic risk group, treatment type (allogeneic BMT versus no transplant), and hemoglobin level were significantly associated with OS (Table 5) . survival of AEL patients in our series was not related to bone marrow or peripheral blood blast counts or to the number of dysplastic lineages. The number of cytopenias in AEL patients did significantly correlate with survival, as patients with a single cytopenia had a better survival (p=0.049) than patients with two or three cytopenias. When we extended these observations to with the subset of MDS patients with erythroid hyperplasia and to patients with AML-MRC and erythroid hyperplasia, we found that these patients had a similar survival to AEL patients and, like AEL patients, OS was not affected by bone marrow blast count. 24 Of note, a prior study on 26 patients with AEL also found that OS had no significant correlation with bone marrow blast count or dysplasia, but did correlate with cytogenetic subgrouping. 8 However, this prior study was based on the FAB classification and thus was limited to AEL cases with blasts comprising ≥ 30% of non-erythroid elements. This previous study also found a higher frequency of chromosome 5 deletion/loss (62% of their cases)
as compared to chromosome 7 deletion/loss (42% of their cases) and raised this as a distinction from therapy-related AML, in which deletion/loss of chromosome 7 is more frequent. 8 In our series, the frequency of chromosome 5 deletion/loss was similar to the frequency of chromosome 7 deletion/loss in AEL. It is noteworthy that T-AEL patients had a much higher incidence of unfavorable cytogenetics (particularly deletion/loss of chromosome 7). In the multivariate analysis including cytogenetic risk group, cytotoxic therapy was not an independent risk factor.
AEL patients with a history of an antecedent hematologic neoplasm also had similar survival to patients presenting de novo. Similar to MDS (but unlike most other types of AML), patients with AEL do not appear to benefit from induction chemotherapy unless followed by BMT. 22 Among patients with AEL lacking high-risk cytogenetics, we found no survival benefit of high-intensity therapy with or without BMT over those receiving supportive care and low-intensity therapies.
The underlying biology of AEL, AML-MRC and MDS with marked erythroid hyperplasia is not well understood. One concern is that prior erythropoietin (EPO) treatment may have caused transient erythroid hyperplasia leading to an erroneous diagnosis of AEL, especially in patients
For personal use only. on July 14, 2017. by guest www.bloodjournal.org From with a preexisting history of MDS or anemia (MDS-AEL cases). However, in one study, MDS patients treated with EPO had relatively reduced rather than increased bone marrow erythroid elements, presumably as a result of EPO promoting functional erythroid differentiation. 25 Furthermore, MDS cases with marked erythroid hyperplasia were no more likely than other MDS cases to be treated with EPO and had similar endogenous EPO levels to MDS cases lacking relative erythroid hyperplasia.
10 EPO was not administrated to any of the patients in our series with de novo AEL and thus could not be responsible for the relative erythroid hyperplasia present in that subgroup. Moreover, our finding that the survival in AEL was similar to MDS with erythroid hyperplasia and was related to neither the absolute blast count nor the blast count as a percentage of non-erythroid elements argue against any significant effect of EPO. Thus, intrinsic cytogenetic and molecular alterations rather than exogenous EPO administration appear to underlie the marked proliferation of erythroid elements that characterize AEL and other myeloid neoplasms with excess blasts and marked erythroid hyperplasia.
In summary, AEL as defined by the 2008 WHO classification presents in a heterogeneous manner, either following MDS or chronic cytopenia, as a therapy-related neoplasm, or de novo.
Disease aggressiveness is strongly associated with cytogenetic findings, but not with blast count, a finding replicated in MDS and AML-MRC cases with erythroid hyperplasia. The extent of morphologic dysplasia, history of MDS, or history of cytotoxic therapy had no independent effect on OS. Our findings suggest that MDS with erythroid hyperplasia, AEL, and AML-MRC with erythroid hyperplasia may form a continuum in which subdivision based on traditional morphologic features such as blast count or dysplastic lineages may not be relevant. In this sense, this group of diseases may be analogous to therapy-related myeloid neoplasms, in which
For personal use only. on July 14, 2017. by guest www.bloodjournal.org From clinical outcome is similar irrespective of classification based on blast count and dysplasia. 26 While AEL cases with high-risk cytogenetics may be best considered as a morphologic subgroup of AML-MRC, the optimal biologic subgrouping of AEL patients lacking high-risk cytogenetics is uncertain; these patients do not appear to benefit from high-intensity therapy and this AEL cytogenetic subgroup may be more akin to MDS with erythroid hyperplasia. Further study is needed to determine the most effective therapy for patients with AEL who are not eligible for allogeneic BMT. 
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